Fulgent Genetics, Inc.

    Jurisdiction
    United States
    LEI
    549300CL6P01M68QJ404
    ISIN
    US3596641098 (FLGT)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    InsiderPie Expert Score
    51 / 100
    Worse than peer group:
    57 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €258.63M
    Gross margin
    40.0%
    EBIT
    -€62.03M
    EBIT margin
    -24.0%
    Net income
    -€43.52M
    Net margin
    -16.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €298.87M +15.6% -€57.27M +31.6%
    €328.42M +9.9% -€52.18M -8.9%
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Gao Hanlin Chief Scientific Officer -1.1K $22.03 -$23.42K
    Xie Jian President and COO -1.1K $22.03 -$24.85K
    Gao Hanlin Chief Scientific Officer -943 $21.48 -$20.26K
    Xie Jian President and COO -1.2K $21.48 -$25.75K
    Gao Hanlin Chief Scientific Officer -548 $21.50 -$11.78K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 10K $175.76K -15K Sell

    Earnings Calls

    Latest earnings call: May 3, 2024 (Q1 2024)

    Add to watchlist

    Notifications